Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Eosinophilic esophagitis patients evaluated at Mayo Clinic will be the source of patients for this study.
Part 1:
20 children and 20 adult eosinophilic esophagitis patients will be retrospectively reviewed for the following:
-
Patient demographics including age, sex, race
-
EoE patient symptoms: dysphagia, food impaction, atopy (asthma, allergic rhinitis, eczema, IgE-mediated food allergies)
-
Mast cell symptoms: flushing, pruritus, urticaria, abdominal cramping with diarrhea
-
Comorbid mast cell disorder diagnosis
-
If performed: Baseline tryptase and 24 hour urine studies: beta-prostaglandin, N-methylhistamine, and leukotriene E4
-
Concurrent medications which histamine mediators: antihistamines, montelukast, aspirin
-
EoE Rx (Concurrent medications which influence esophageal eosinophilia): PPI, steroids, elimination diet
-
Endoscopic findings (rings, furrows)
Esophageal biopsies will further be analyzed based on tryptase staining for mast cells and then low and peak mast cells/HPF will be identified for the esophageal biopsies. Also, peak eosinophils/HPF will be identified in the esophageal biopsies with H&E staining.
Part 2:
The group with higher mast cells/HPF will be the cohort for Part 2 of the study.
At least 20 eosinophilic esophagitis patients will be prospectively reviewed for the following:
-
Patient demographics including age, sex, race
-
EoE patient symptoms: dysphagia, food impaction, atopy (asthma, allergic rhinitis, eczema, IgE-mediated food allergies)
-
Mast cell symptoms: flushing, pruritus, urticaria, abdominal cramping with diarrhea
-
Comorbid mast cell disorder diagnosis
-
Baseline tryptase and 24 hour urine studies: beta-prostaglandin, N-methylhistamine, and leukotriene E4
-
Concurrent medications which histamine mediators: antihistamines, montelukast, aspirin
-
EoE Rx (Concurrent medications which influence esophageal eosinophilia): PPI, steroids, elimination diet
-
Endoscopic findings (rings, furrows)
Esophageal biopsies will further be analyzed based on tryptase staining for mast cells and then low and peak mast cells/HPF will be identified for the esophageal biopsies. Peak eosinophils/HPF will be identified in the esophageal biopsies with H&E staining.
We aim to see if there is an elevated histamine release (via serum tryptase and 24 hour urine N-methyl histamine, beta-prostaglandin, and leukotriene E4) in EoE patients and further correlated with density of tryptase staining on esophageal biopsies.